CNR Institutional Research Information System

DE ROSA, VIVIANA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 1.142
NA - Nord America 636
EU - Europa 347
SA - Sud America 142
AF - Africa 12
OC - Oceania 1
Totale 2.280
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 593
SG - Singapore 442
CN - Cina 221
HK - Hong Kong 213
IT - Italia 133
BR - Brasile 113
VN - Vietnam 88
FR - Francia 65
JP - Giappone 47
BD - Bangladesh 45
NL - Olanda 40
KR - Corea 33
FI - Finlandia 28
CA - Canada 23
DE - Germania 23
GB - Regno Unito 19
AR - Argentina 13
MX - Messico 13
IN - India 12
EC - Ecuador 9
ES - Italia 7
IQ - Iraq 7
ZA - Sudafrica 7
ID - Indonesia 5
IE - Irlanda 5
RU - Federazione Russa 5
JO - Giordania 4
TR - Turchia 4
CO - Colombia 3
IL - Israele 3
JM - Giamaica 3
KH - Cambogia 3
LV - Lettonia 3
UA - Ucraina 3
AT - Austria 2
MA - Marocco 2
NP - Nepal 2
PH - Filippine 2
PK - Pakistan 2
PL - Polonia 2
SK - Slovacchia (Repubblica Slovacca) 2
UZ - Uzbekistan 2
VE - Venezuela 2
AL - Albania 1
AM - Armenia 1
AO - Angola 1
AU - Australia 1
AZ - Azerbaigian 1
CZ - Repubblica Ceca 1
DK - Danimarca 1
DM - Dominica 1
DO - Repubblica Dominicana 1
DZ - Algeria 1
ET - Etiopia 1
GR - Grecia 1
GT - Guatemala 1
HN - Honduras 1
IM - Isola di Man 1
KZ - Kazakistan 1
LB - Libano 1
LT - Lituania 1
PE - Perù 1
PS - Palestinian Territory 1
PT - Portogallo 1
RO - Romania 1
RS - Serbia 1
SA - Arabia Saudita 1
SE - Svezia 1
TH - Thailandia 1
UY - Uruguay 1
Totale 2.280
Salva come PNG Salva come JPEG
Città #
Singapore 279
Hong Kong 212
Santa Clara 185
San Jose 71
Beijing 64
Hefei 61
Naples 53
Ashburn 52
Lauterbourg 49
Tokyo 42
Seoul 33
Ho Chi Minh City 27
Los Angeles 25
Hanoi 24
Lappeenranta 16
New York 15
Casandrino 13
Frankfurt am Main 11
Helsinki 11
São Paulo 11
Council Bluffs 9
Chicago 8
Buffalo 7
Belleville 6
Boardman 6
Mexico City 6
Rome 6
Brooklyn 5
Dallas 5
Des Moines 5
Dublin 5
Milan 5
Orem 5
Amsterdam 4
Da Nang 4
Düsseldorf 4
Hangzhou 4
London 4
Amman 3
Atlanta 3
Baghdad 3
Bauru 3
Belo Horizonte 3
Bengaluru 3
Buenos Aires 3
Carapicuíba 3
Chennai 3
Guayaquil 3
Haiphong 3
Istanbul 3
Johannesburg 3
Minamishinagawa 3
Montreal 3
Paris 3
Phnom Penh 3
Phoenix 3
Poplar 3
Quito 3
Ribeirão Preto 3
Riga 3
Shanghai 3
Toronto 3
Abingdon 2
Biên Hòa 2
Bonito 2
Boston 2
Bratislava 2
Can Tho 2
Charlotte 2
Clinton Township 2
Columbus 2
Covina 2
Erbil 2
Falkenstein 2
Florence 2
Fortaleza 2
Ha Long 2
Hammond 2
Houston 2
Hòa Bình 2
Hải Dương 2
Keyport 2
Lajeado 2
Lancaster 2
Maceió 2
Madrid 2
Manchester 2
Manila 2
Minneapolis 2
Moscow 2
Munich 2
Nha Trang 2
Palermo 2
Phủ Lý 2
Pisa 2
Piscataway 2
Porto Alegre 2
Praia Grande 2
Quận Chín 2
Rancho Cucamonga 2
Totale 1.500
Salva come PNG Salva come JPEG
Nome #
Monitoring Reversal of Concurrent Mechanisms of Resistance to EGFR TKIs in Non-Small Cell Lung Cancer by 18F-FLT PET/CT 90
Changes of Glycolytic Pathway in Response to Efficient Inhibition of EGFR Signaling in Non-small Cell Lung Cancer (NSCLC) 87
Early reduction of 18F-FDG uptake in non-small lung cancer treated with EGFR tyrosine kinase inhibitors reflects reversal of Warburg effect and reactivation of oxidative phosphorylation. 87
18F-FLT PET/CT imaging and inhibition of multiple signaling pathways downstream EGFR and MET receptors in resistant NSCLC 75
Molecular mechanisms of decreased aerobic glycolysis in non-small lung cancer treated with EGFR tyrosine kinase inhibitors. European Society for Molecular Imaging Meeting 70
ATM inhibition blocks glucose metabolism and amplifies the sensitivity of resistant lung cancer cell lines to oncogene driver inhibitors 69
Immune-Cell-Derived Exosomes as a Potential Novel Tool to Investigate Immune Responsiveness in SCLC Patients: A Proof-of-Concept Study 69
Inositol Trisphosphate Receptor Type 3-mediated Enhancement of EGFR and MET Cotargeting Efficacy in Non-Small Cell Lung Cancer Detected by F-18-fluorothymidine 65
18F-FLT PET/CT for Detection of Functional Cross-talk between MET and EGFR in Non-small Cell Lung Cancer Resistant to EGFR Inhibitors 65
Multimodal imaging of tumor invasion by targeting integrin ?v?3 in a preclinical model of lung metastasis 63
Non-invasive detection of epithelial mesenchymal transition phenotype and metastatic dissemination of lung cancer by liquid biopsy 62
Exosome-like Systems: From Therapies to Vaccination for Cancer Treatment and Prevention-Exploring the State of the Art 61
Changes of glycolytic pathway and upregulation of oxidative phosphorylation in BCR-ABL-driven human leukemia cells treated with imatinib 60
ITGB1 and DDR activation as novel mediators in acquired resistance to osimertinib and MEK inhibitors in EGFR-mutant NSCLC 59
Integrin-dependent cell adhesion to neutrophil extracellular traps through engagement of fibronectin in neutrophil-like cells 56
PBMCs as Tool for Identification of Novel Immunotherapy Biomarkers in Lung Cancer 56
Combined Therapeutic Strategies Based on the Inhibition of Non-Oncogene Addiction to Improve Tumor Response in EGFR- and KRAS-Mutant Non-Small-Cell Lung Cancer 56
A reversible shift of driver dependence from egfr to notch1 in non-small cell lung cancer as a cause of resistance to tyrosine kinase inhibitors 55
Preclinical imaging for targeting cancer immune evasion 52
Non-Canonical Role of PDK1 as a Negative Regulator of Apoptosis through Macromolecular Complexes Assembly at the ER–Mitochondria Interface in Oncogene-Driven NSCLC 52
Dynamic roles of neutrophil extracellular traps in cancer cell adhesion and activation of Notch 1-mediated epithelial-to-mesenchymal transition in EGFR-driven lung cancer cells 52
Preclinical Imaging in Targeted Cancer Therapies 45
Coordinate modulation of glycolytic enzymes and OXPHOS by imatinib in BCR-ABL driven chronic myelogenous leukemia cells 44
Neutrophil Extracellular Traps as an Adhesion Substrate for Different Tumor Cells Expressing RGD-Binding Integrins 44
Notch1-dependent targets in cancer stem cell resistance to EGFR inhibitors in oncogene-driven non-small cell lung cancer 43
Molecular imaging for detection of sensitivity and resistance to EGFR tyrosine kinase inhibitors in non-small cell lung cancer 43
Monitoring the effects of combined treatment with EGFR and MET inhibitors in non-small cell lung cancer and synergy quantification by 18F-FLT PET/CT 42
Small animal SPECT with 99m-Tc-Hynic-annexin V for detection of non-small cell lung cancer resistance to EGFR antagonists and its reversal by Bcl-xL inhibitors 38
18F-FLT PET/CT imaging of inositol trisphosphate receptor type 3-mediated enhancement of EGFR and MET co-targeting efficacy in non-small cell lung cancer 38
Preclinical imaging in oncology: advances and perspectives 37
18F-FLT PET/CT as a surrogate biomarker for synergy quantification in EGFR targeted combination therapy of NSCLC 36
Early F-18-FDG uptake as a reliable imaging biomarker of T790M-mediated resistance but not MET amplification in non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors 35
Effect of IL-1β on NSCLC-Derived Small Extracellular Vesicles as Actors in Mediating Cancer Progression and Evading Immune System 35
18F-FLT PET/CT to Detect Reversal of Concurrent Mechanisms of Resistance to EGFR TKIs in Non-Small Cell Lung Cancer. 33
Monitoring reversal of MET-mediated resistance to EGFR tyrosine kinase inhibitors in non-small cell lung cancer using 3'-deoxy-3'-[18F]-fluorothymidine positron emission tomography 31
Combination of Abeta secretion and oxidative stress in an Alzheimer-like cell line leads to the over-expression of the nucleotide excision repair proteins DDB2 and XPC 29
18F-FLT PET/CT to detect reversal of EGFR TKI resistance due to MET amplification by MET inhibitors in NSCLC 29
Small animal SPECT with 99m-Tc-Hynic-annexin V for detection of non-small cell lung cancer resistance to EGFR antagonists and its reversal by Bcl-xL inhibitors 28
18F-FLT PET/CTas a surrogate biomarker for synergy quantification in EGFR targeted combination therapy of NSCLC 28
18F-FLT PET/CT to Detect Reversal of Concurrent Mechanisms of Resistance to EGFR TKIs in Non-Small Cell Lung Cancer 27
Combined Imaging with 18F-FLT PET/CT and 99m-Tc-Hynic-Annexin V SPECT for Personalized Therapy with EGFR Antagonists and Bcl-xL Inhibitors in Non-Small Cell Lung Cancer 27
Does a role for selenium in DNA damage repair explain apparent controversies in its use in chemoprevention? 27
[18]F-FLT PET-CT to detect reversal of EGFR TKI resistance due to MET amplification by MET inhibitors in NSCLC. 26
Neutrophil extracellular traps as drivers of epithelial-mesenchymal transition in cancer cells 26
Effect of Soluble Factors Released from Porcine Freeze-Dried Lung Tissue (FDLT) on Modulation of Cell Growth and EMT Signature in Non-Small Cell Lung Cancer (NSCLC)—A Preliminary In Vitro Study 24
Reversal of Warburg Effect and Reactivation of Oxidative Phosphorylation by Differential Inhibition of EGFR Signaling Pathways in Non-Small Cell Lung Cancer 24
Low doses of selenium specifically stimulate the repair of oxidative DNA damage in LNCaP prostate cancer cells 24
Molecular imaging for detection of sensitivity and resistance to EGFR tyrosine kinase inhibitors in non-small cell lung cancer 22
DNA-PK inhibition sustains the antitumor innate immune response in small cell lung cancer 21
Synergistic effects of oncogene inhibition and pyruvate dehydrogenase kinase blockade in resistant NSCLC cells 21
Early 18F-FDG uptake as a reliable imaging biomarker of T790M-mediated resistance but not MET amplification in NSCLC 21
Alzheimer's Disease-Associated Neurotoxic Peptide Amyloid-B Impairs Base Excision Repair in Human Neuroblastoma Cells 20
Addition of metformin to anti-PD-1/PD-L1 drugs activates antitumor immune response in peripheral immune cells of NSCLC patients 18
Novel applications of liquid Biopsy: Comprehensive methodology for circulating biomarker exploration in peripheral blood 12
Totale 2.359
Salva come PNG Salva come JPEG
Categoria #
all - tutte 7.404
article - articoli 6.744
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 14.148
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2023/202435 0 0 0 0 0 0 0 0 5 8 7 15
2024/2025861 15 14 79 42 195 40 1 58 54 62 156 145
2025/20261.412 62 95 73 136 328 90 215 59 116 96 63 79
2026/202751 51 0 0 0 0 0 0 0 0 0 0 0
Totale 2.359